5 Allergy Headlines You Missed in May 2026

May 2026 was a busy month for allergy and immunology. Phase 3 data on a one-time gene editing therapy for hereditary angioedema (HAE) made headlines, updated guidelines formalized a first-line oral treatment option, and investigators continued to push the boundaries of what individualized care looks like for patients managing food allergy and chronic spontaneous urticaria (CSU). Deeper in the literature, new mechanistic data on house dust mite sublingual immunotherapy (SLIT) offers a clearer picture of what immune tolerance actually looks like at the cellular level.